BlossomHill Therapeutics, Inc. (BLSM)

BlossomHill Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that designs small-molecule drugs for cancer. The company was incorporated in 2020 and completed its initial public offering on Nasdaq in August 2026.

Its lead program, BH-30643, is an EGFR inhibitor designed to act against a broad range of EGFR mutations, being developed for patients with advanced EGFR-mutant non-small cell lung cancer. A second clinical program, BH-30236, is a macrocyclic CLK inhibitor under study in relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome. The company also has earlier-stage candidates in its pipeline.